See the DrugPatentWatch profile for esperoct
EspeRoct is a recombinant activated Factor VII (rFVIIa) concentrate used to treat bleeding episodes in individuals with hemophilia A or B, with or without inhibitors [1]. It is also indicated for surgical bleeding in these patients [1].
How does EspeRoct work?
EspeRoct functions by providing activated Factor VII, which initiates the coagulation cascade [1]. This leads to the formation of thrombin, which converts fibrinogen to fibrin, thus stabilizing the blood clot and stopping bleeding [1].
Who makes EspeRoct?
Novartis developed and markets EspeRoct [2].
When did EspeRoct receive approval?
EspeRoct received approval from the U.S. Food and Drug Administration (FDA) in 2015 [3].
What are the clinical benefits of EspeRoct?
Clinical trials have demonstrated EspeRoct's efficacy in treating bleeding episodes in hemophilia patients [1]. Studies showed successful treatment of hemarthroses, muscle, and mucocutaneous bleeding [1]. It has also been shown to be effective in managing perioperative bleeding [1].
What are the potential risks and side effects of EspeRoct?
The most common side effects associated with EspeRoct include [1]:
* Pyrexia (fever)
* Headache
* Nausea
* Anemia
* Nasopharyngitis (common cold symptoms)
A serious, but rare, risk associated with rFVIIa products is thromboembolic events, such as stroke, myocardial infarction, pulmonary embolism, and venous thromboembolism [1]. These events can be fatal [1].
How does EspeRoct compare to other treatments for hemophilia bleeding?
EspeRoct is a bypass agent, meaning it bypasses the defective Factor VIII or Factor IX in hemophilia [1]. Other treatment options include factor replacement therapy (using Factor VIII or Factor IX concentrates) and other bypassing agents like NovoSeven RT [4]. The choice of treatment often depends on the patient's specific condition, presence of inhibitors, and physician preference [4].
What is the patent status and exclusivity period for EspeRoct?
Information regarding specific patents and their expiry dates for EspeRoct can be found through resources like DrugPatentWatch.com [5]. DrugPatentWatch tracks patent information for pharmaceuticals, which can indicate periods of market exclusivity [5].
What is the cost of EspeRoct?
The cost of EspeRoct can vary significantly based on dosage, insurance coverage, and geographic location [6]. As with many specialized biologic therapies, it is a high-cost medication [6].
What are the patient concerns regarding EspeRoct?
Patients and caregivers often have concerns about the effectiveness of EspeRoct in controlling bleeding, the frequency of administration, potential side effects, and the long-term management of hemophilia [7]. They also seek information on how EspeRoct compares to other treatment options in terms of convenience and outcomes [7].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206393s000lbl.pdf
2. https://www.novartis.com/our-impact/patients-and-diseases/hemophilia
3. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-safety-communications (General FDA drug approvals reference)
4. https://www.hemophilia.org/healthcare-professionals/clinical-practice-guidelines (General hemophilia treatment information)
5. https://drugpatentwatch.com/
6. https://www.goodrx.com/news/health-news/drug-pricing/ (General information on drug pricing variability)
7. https://www.hemophilia.org/patients (Patient advocacy and information resources)